Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP clinical trials
How each study uses Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
2 studies that test it; most in 2019 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
National Cancer Institute (NCI) (2) · Nouscom SRL (1)
Often tested with
Tested in the same studies.
MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP (2) · GAD-209 (1) · MVA-209 (1)
Studies
Open first, then newest update. How each study uses Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch SyndromeNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07937696Written as Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPHow we know
- Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05078866Written as Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPHow we know
- Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsActive, not recruitingPhase 1/2Nouscom SRLNCT04041310Written as GAd20-209-FSP, RP2DHow we know
What changed recently
From the registry's own updates since Oct 22, 2026.